The Oncology Institute, Inc.
TOI
$3.78
$0.020.53%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 461.04M | 424.38M | 403.15M | 393.41M | 378.93M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 461.04M | 424.38M | 403.15M | 393.41M | 378.93M |
| Cost of Revenue | 392.73M | 360.62M | 343.88M | 339.42M | 325.19M |
| Gross Profit | 68.31M | 63.75M | 59.28M | 54.00M | 53.74M |
| SG&A Expenses | 102.39M | 103.79M | 104.75M | 107.83M | 111.17M |
| Depreciation & Amortization | 7.02M | 6.87M | 6.58M | 6.29M | 6.16M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 502.14M | 471.28M | 455.21M | 453.53M | 442.52M |
| Operating Income | -41.11M | -46.90M | -52.06M | -60.12M | -63.59M |
| Income Before Tax | -66.41M | -66.02M | -64.36M | -64.66M | -70.55M |
| Income Tax Expenses | -131.00K | -131.00K | -- | -- | -314.00K |
| Earnings from Continuing Operations | -66.28 | -65.89 | -64.36 | -64.66 | -70.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -66.28M | -65.89M | -64.36M | -64.66M | -70.24M |
| EBIT | -41.11M | -46.90M | -52.06M | -60.12M | -63.59M |
| EBITDA | -34.09M | -40.04M | -45.48M | -53.83M | -57.43M |
| EPS Basic | -0.64 | -0.68 | -0.70 | -0.71 | -0.77 |
| Normalized Basic EPS | -0.46 | -0.49 | -0.50 | -0.54 | -0.60 |
| EPS Diluted | -0.65 | -0.69 | -0.71 | -0.72 | -0.78 |
| Normalized Diluted EPS | -0.46 | -0.49 | -0.50 | -0.54 | -0.60 |
| Average Basic Shares Outstanding | 343.43M | 321.48M | 303.03M | 300.16M | 297.98M |
| Average Diluted Shares Outstanding | 343.43M | 321.48M | 303.03M | 300.16M | 297.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |